Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity studynews2025-01-07T15:23:52+00:00January 7th, 2025|Endpoints News|
Profluent debuts AI model for CRISPR gene editing designnews2025-01-07T12:00:48+00:00January 7th, 2025|Endpoints News|
Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia with Orna Therapeuticsnews2025-01-07T12:00:02+00:00January 7th, 2025|Endpoints News|
Ken Song’s Candid licenses a T cell engager from WuXi Bionews2025-01-07T11:50:30+00:00January 7th, 2025|Endpoints News|
Highlander Health acquires Target RWE to improve clinical trialsnews2025-01-07T11:00:39+00:00January 7th, 2025|Endpoints News|
Acelyrin reports mid-stage win for potential Tepezza challenger in thyroid eye diseasenews2025-01-06T21:30:23+00:00January 6th, 2025|Endpoints News|
Oculis’ eye drug clears Phase 2 in France as US development beckonsnews2025-01-06T11:40:47+00:00January 6th, 2025|Endpoints News|
GSK’s Nucala bags another China approval, but biggest test yet to comenews2025-01-03T12:02:52+00:00January 3rd, 2025|Endpoints News|
After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity playnews2025-01-03T11:33:19+00:00January 3rd, 2025|Endpoints News|
FDA adcomm to review Novartis’ Fabhalta in ultra-rare kidney diseasenews2025-01-02T19:15:51+00:00January 2nd, 2025|Endpoints News|
